InsidersTradesSigma
Follow the Amphastar Pharmaceuticals, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Amphastar Pharmaceuticals, Inc. has recorded 214 public disclosures. Market capitalisation: €958.4m. The latest transaction was filed on 3 September 2026 (Cession). Among the most active insiders: Petersen Floyd F.. The full history is accessible without an account.
214
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€12m
65 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Amphastar Pharmaceuticals, Inc. Hold (neutral), based on 6 analysts. Average price target: US$22.50.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,496 of 29,062 companies
72.0
score / 100
Value83
Quality61
FCF yld12%
Earn yld10%
EV/EBITDA7.6x
ROE10%
Gross mgn49%
Net mgn14%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations214 total
47,101 shares@ US$21.000.11% mcap100.0% of flowCommon StockSEC144:0001969223-26-000926
7,973 shares@ US$20.300.018% mcap6.0% of flowCommon StockSEC:0001047579-26-000005:0
7,973 shares@ US$20.310.018% mcap100.0% of flowCommon StockSEC144:0001969223-26-000880
8,180 shares@ US$22.480.020% mcap4.2% of flowCommon StockSEC:0001263136-26-000012:1
5,053 shares@ US$19.790.011% mcap2.3% of flowCommon StockSEC:0001263136-26-000012:0
8,180 shares@ US$22.480.020% mcap4.5% of flowCommonSEC144:0001969223-26-000860
7,886 shares0Common StockSEC:0002141303-26-000005:0
1,500 shares0Common StockSEC:0001047579-26-000003:0
769 shares@ US$18.450.0016% mcap1.9% of flowCommon StockSEC:0001379941-26-000003:1
8,143 shares0Common StockSEC:0001033511-26-000003:0
8,143 shares0Common StockSEC:0001047579-26-000003:1
8,143 shares0Common StockSEC:0001379941-26-000003:0
8,143 shares0Common StockSEC:0001611283-26-000003:0
8,143 shares0Common StockSEC:0001866024-26-000003:0
8,143 shares0Common StockSEC:0002075974-26-000003:0
1,973 shares@ US$18.180.9% of flowCommon StockSEC:0001263136-26-000010:0
1,033 shares@ US$18.180.6% of flowCommon StockSEC:0001743927-26-000010:0
9,784 shares@ US$18.180.8% of flowCommon StockSEC:0000889740-26-000007:0
35,450 shares0Common StockSEC:0001743927-26-000008:0
58,693 shares0Common StockSEC:0001263136-26-000008:0
180,504 shares0Common StockSEC:0000889740-26-000005:0
3,077 shares@ US$19.340.0068% mcap0.3% of flowCommon StockSEC:0000889740-26-000003:1
25 of 214 declarations
关于 Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc.（股票代码：AMPH）是一家在美国纳斯达克市场交易的美国上市生物制药公司。Amphastar 总部位于加利福尼亚州兰乔库卡蒙加，自称是一家综合性制药公司，专注于开发、制造和商业化技术上具有挑战性的注射剂、鼻内和吸入产品以及活性药物成分（API）。该公司于 1996 年在加利福尼亚州注册成立，此后通过收购和内部平台开发不断扩张。（[amphastar.com](https://www.amphastar.com/about-us.html?utm_source=openai)） 从股票分析的角度来看，Amphastar 的商业模式将成熟的商业基础与旨在深化其在专业仿制药和生物制剂领域影响力的产品线相结合。该公司销售超过 25 种处方产品和一种非处方产品 Primatene MIST®，其目前最大的收入贡献者包括 BAQSIMI® 胰高血糖素鼻粉、Primatene MIST®、胰高血糖素、肾上腺素和利多卡因。管理层还强调了涵盖 ANDA、BLA 和生物类似胰岛素候选产品的开发项目，这使得 Amphastar 不仅仅是一家传统的商品仿制药制造商：它正在追求一种具有更高复杂性和更强进入壁垒的产品组合。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm?utm_source=openai)） Amphastar 的竞争优势来自于制造复杂性和配方专业知识，而不仅仅是规模。该公司强调在无菌注射剂、急救药物和专业递送形式方面的专业知识，这些领域对监管合规性、过程控制和供应可靠性至关重要。它还表示，它在美国、中国和欧洲运营着五家制造工厂，以及一个先进的研究中心，而所有成品都在美国制造。这种布局支持了质量、冗余和客户信任，但该公司仍然面临成熟仿制药的价格压力以及关键医院导向产品的竞争。（[amphastar.com](https://www.amphastar.com/about-us.html?utm_source=openai)） 最近的发展对投资案例至关重要。Amphastar 的 BAQSIMI® 特许经营权通过 2023 年对该产品的收购得到加强，并在 2025 年初，该公司承担了全面的全球分销职责，有助于收入确认并使 Amphastar 对该品牌的商业推广拥有更大的控制权。该公司还通过在 2024 年推出沙丁胺醇和在 2025 年推出蔗糖铁等产品，不断更新其产品组合。2025 年 7 月，Amphastar 宣布在其兰乔库卡蒙加总部进行为期多年的美国制造能力扩张，其称之为公司历史上最大的国内基础设施投资。这些行动表明，公司明确专注于供应链控制、产能扩张和加强其专业产品特许经营权。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm?utm_source=openai)）
